Peptide Therapy
FDA 2026 Peptide Compounding Update: What the Category Lists Say. Part of the Peptide Therapy library by Dr. med. univ. Julian Douwes
How specific probiotic strains shift Th2-dominant immune responses in allergic rhinitis, eczema, food allergy, and asthma — a clinical guide to strain selection and protocol design.
What FDA's May 2026 503A category update actually changed for peptides: GHK-Cu, VIP, the withdrawn category 2 nominations, and what it means for US access.
Comprehensive guide to peptide legality in 2026. FDA regulations, EU framework, Australia's scheduling, compounding pharmacy rules, and grey market risks explained by a physician.
